Delayed release pharmaceutical formulation
AssigneeTillotts Pharma AG
InventorsDaniel PREISIG, Maxim PUCHKOV, Joerg HUWYLER, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALEZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.
Claims16
A delayed release pharmaceutical formulation for delivering an active agent to the intestine, comprising carrier particles and at least one active agent associated with the carrier particles, wherein the carrier particles are porous particles and are surrounded by a material for intestinal targeting.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the at least one active agent is adsorbed onto and/or absorbed into the carrier particles.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the carrier particles are associated with at least 15% by weight, preferably at least 20% by weight of the at least one active agent based on the total weight of the carrier particles including the weight of the at least one active agent.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the active agent is selected from the group consisting of anti-inflammatory agents, anti-infective agents, immunomodulators and antibodies.
The delayed release pharmaceutical formulation according any of the preceding claims, wherein the carrier particles are surrounded by a coating of the material for intestinal targeting.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the carrier particles are within a matrix of the material for intestinal targeting.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the material for intestinal targeting comprises a compound which is insoluble in the intestinal juice at a pH below 5 and which is soluble in the intestinal juice at a pH at or above 5.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the material for intestinal targeting is a material for colon targeting.
The delayed release pharmaceutical formulation according to any of the preceding claims wherein the carrier particles are at least partially coated with a compound which imparts hydrophobicity or hydrophilicity to the surface of the carrier particles.
The delayed release pharmaceutical formulation according to any of the preceding claims, wherein the carrier particles are at least partially coated with a mucoadhesive compound and/or sustained release coating.
Dependencies are inferred from the claim text.